<DOC>
	<DOCNO>NCT01484171</DOCNO>
	<brief_summary>To compare antitumor efficacy toxicity Idarubicin cytarabine combination infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cell patient newly diagnose high-risk acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>HLA-mismatched Microtransplantation High Risk Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Having sign informed consent 2 . Diagnosis base FrenchAmericanBritish ( FAB ) WHO criteria . 3 . Age ≥ 7 year old 4 . Age ＜ 60 year old 1.Patients blast crisis chronic myeloid leukemia acute promyelocytic leukemia</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>idarubicin</keyword>
	<keyword>Microtransplantation</keyword>
</DOC>